DOCSLIB.ORG
  • Sign Up
  • Log In
  • Upload
  • Sign Up
  • Log In
  • Upload
  • Home
  • »  Tags
  • »  Entacapone

Entacapone

  • Novel Neuroprotective Compunds for Use in Parkinson's Disease

    Novel Neuroprotective Compunds for Use in Parkinson's Disease

  • (12) Patent Application Publication (10) Pub. No.: US 2013/0253056A1 Nemas Et Al

    (12) Patent Application Publication (10) Pub. No.: US 2013/0253056A1 Nemas Et Al

  • PSP: Some Answers

    PSP: Some Answers

  • Azilect, INN-Rasagiline

    Azilect, INN-Rasagiline

  • Compositions for Continuous Administration of Dopa

    Compositions for Continuous Administration of Dopa

  • Oral Systemic Therapy Pharmacy Toolkit

    Oral Systemic Therapy Pharmacy Toolkit

  • New Drugs Approved in FY 2014

    New Drugs Approved in FY 2014

  • Opicapone for the Management of End-Of-Dose Motor Fluctuations in Patients with Parkinson’S Disease Treated with L-DOPA

    Opicapone for the Management of End-Of-Dose Motor Fluctuations in Patients with Parkinson’S Disease Treated with L-DOPA

  • 207145Orig1s000

    207145Orig1s000

  • 212489Orig1s000 SUMMARY REVIEW

    212489Orig1s000 SUMMARY REVIEW

  • A Spanish Consensus on the Use of Safinamide for Parkinson's Disease in Clinical Practice

    A Spanish Consensus on the Use of Safinamide for Parkinson's Disease in Clinical Practice

  • EUROPEAN PHARMACOPOEIA 10.0 Index 1. General Notices

    EUROPEAN PHARMACOPOEIA 10.0 Index 1. General Notices

  • Catechol-O-Methyltransferase Inhibitor, on the Motor Response to Acute Treatment with Levodopa in Patients with Parkinson's Disease

    Catechol-O-Methyltransferase Inhibitor, on the Motor Response to Acute Treatment with Levodopa in Patients with Parkinson's Disease

  • DRUG TREATMENTS for Parkinson's

    DRUG TREATMENTS for Parkinson's

  • PRODUCT INFORMATION Entacapone Item No

    PRODUCT INFORMATION Entacapone Item No

  • Comtan (Entacapone), the Cmax Is Approximately 1.2 Mcg Per Ml

    Comtan (Entacapone), the Cmax Is Approximately 1.2 Mcg Per Ml

  • C B G Summary Public Assessment Report Generics Levodopa

    C B G Summary Public Assessment Report Generics Levodopa

  • Initial Experience of the Levodopa–Entacapone–Carbidopa Intestinal Gel in Clinical Practice

    Initial Experience of the Levodopa–Entacapone–Carbidopa Intestinal Gel in Clinical Practice

Top View
  • Rasagiline NDC 0378- -93 Dispense in a Tight, Light-Resistant Mesylate Equivalent to 0.5 Mg 1270 Container As Defined in the USP of Rasagiline
  • Comtan, INN-Entacapone
  • Parkinson's Disease with End-Of-Dose Motor Fluctuations: Opicapone
  • Carbidopa-Levodopa-Entacapone (Stalevo)
  • Parkinson's Treatment “Tips & Pearls”
  • PSP: Some Answers
  • Levodopa/Carbidopa/Entacapone Orion, INN-Levodopa, Carbidopa
  • Appendix B - Product Name Sorted by Applicant
  • Perioperative Medication Management - Adult/Pediatric - Inpatient/Ambulatory Clinical Practice Guideline
  • Safinamide (Xadago) Reference Number: ERX.NPA.45 Effective Date: 09.01.17 Last Review Date: 02.21 Line of Business: Commercial, Medicaid Revision Log
  • PUBLIC SUMMARY DOCUMENT Product: RASAGILINE, Tablet, 1 Mg, Azilect® Sponsor: Lundbeck Australia Pty Ltd Date of PBAC Consideration: July 2011
  • Second Quarter 2019 Update: Changes to the Highmark Drug Formularies
  • Therapeutic Drug Class
  • ENTAPONE 1. Product Name 2. Qualitative and Quantitative
  • Opioid Codrugs for Pain Management
  • Parkinson's Disease Medications
  • Levodopa/Carbidopa/Entacapone Orion, INN-Levodopa, Carbidopa
  • Practical Guidelines for Management of Parkinson Disease


© 2024 Docslib.org    Feedback